Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients - Trial NCT05143736
Access comprehensive clinical trial information for NCT05143736 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhujiang Hospital and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhujiang Hospital
Timeline & Enrollment
N/A
Jan 10, 2022
Jan 31, 2023
Primary Outcome
All-cause death at 28 days
Summary
In this prospective, multicentered , diagnostic trial, nasal and fecal specimens will
 collected from patients with sepsis in two critical care units(ICU) at the enrollment day
 ,the third, seventh, and fourteen days after enrollment or until ICU discharge (whatever come
 first). Total DNA from the nasal and fecal specimens will be extracted, amplified, and
 sequenced to determined the characteristics of gut microbiota and nasal microbiota. Finally,
 the characteristics of gut microbiota and nasal microbiota combined clinical information will
 be used to construct a prediction model to predict the prognosis of sepsis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05143736
Non-Device Trial